| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() DG DISPATCH - AAP: DDAVP (Desmopressin Acetate) Effective For Children With Nocturnal Enuresis By Lara Pullen Special to DG News
CHICAGO, IL -- October 30, 2000 -- DDAVP (desmopressin acetate) is a safe and effective long-term treatment for patients with nocturnal enuresis. At the American Academy of Pediatrics Annual Meeting, held here this week, Dr. Mark R. Zaontz of the Robert Wood Johnson Medical School in Camden, New Jersey, presented the results of a retrospective review addressing the safety and efficacy of long-term treatment with DDAVP. Dr. Zaontz and colleagues randomly selected the charts of 114 children with nocturnal enuresis. The parents were interviewed via written questionnaires or telephone to determine the enuretic history of the children. A total of 76 children and families completed the interviews. Forty-two percent of the families with children on DDAVP reported no wet nights. The patients who were on DDAVP for longer than one year had an average number of 5.7 wet nights per week prior to treatment and 0.6 wet nights per week after treatment. After cessation of DDAVP therapy, 20 percent of the children were 100 percent dry. Thirty four percent of the children were switched from nasal to oral treatment, with the majority (64 percent) experiencing no change in the number of wet nights. Oral therapy did result in an improvement, however, for 30 percent of the children. Overall, the investigators found that 61 percent of the families reported either an excellent or very good response on DDAVP and their children remained on treatment for up to seven years. In addition, they found that oral DDAVP appeared to result in improved dryness when compared with the nasal spray.
|